Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
After the first 100 blogs, it is appropriate to reflect on reader preferences. When I arbitrarily select a topic, it is not always clear whether what interests me also interests you. Since its start 1½ years ago, this blog has grown steadily in readership. So we did a few things right Continue reading ALLPHASE PHARMA – THE FIRST 100 BLOG POSTS
SH: My dear Watson, did you read the news of the astonishing debacle that befell Mme Erava and made the headlines, creating anxiety of hitherto unknown proportions in Tetraland? Dr.W.: A disaster of epic proportions, for sure, and a mystery, an explanation which will require some very expert investigation. There is Continue reading Mme Erava and The Mysterious Case of Auto-Combustion
Dalbavancin has changed hands a few times in its development history, moving from Lilly to Vicuron, then Pfizer and ultimately Durata. The original NDA for dalbavancin was submitted to FDA on Dec. 21, 2004. Pfizer acquired dalbavancin as a “Phase 3 completed” drug ready for world-wide marketing on June 15, 2005. The Continue reading Dalbavancin Approval Issues: A Case of Much Ado About Nothing